No Data
No Data
CLARITY MEDICAL: INTERIM REPORT 2024/2025
Clarity Medical Group Holding's Loss Narrows for Six Months to September
In the "Performance" report, clarity medical (01406.HK) has narrowed its mid-term loss to 18.57 million yuan.
Clarity medical (01406.HK) announced its interim performance for the six months ended September, with revenue recorded at 87.2 million yuan, a 14.2% year-on-year decrease. Losses narrowed from 20.02 million yuan in the same period last year to 18.57 million yuan, with a loss per share of 3.5 cents. No interim dividend will be distributed.
Clarity medical (01406.HK) interim earnings are approximately 87.2 million HKD, a year-on-year decrease of 14.2%.
On November 27, Gelonghui reported that Clarity Medical (01406.HK) announced that the group's revenue decreased from approximately 0.102 billion Hong Kong dollars for the six months ending September 30, 2023, to approximately 87.2 million Hong Kong dollars during the interim period of 2024, a decline of 14.2%. To this end, the group is actively implementing cost-cutting measures without compromising service quality. In particular, the adjusted net loss (which refers to a one-time non-recurring impairment loss of factory, equipment, and right-of-use assets) decreased from approximately 20 million Hong Kong dollars for the six months ending September 30, 2023, to approximately 1.
CLARITY MEDICAL: INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
Clarity Medical (01406.HK) is planning to hold a board of directors meeting on November 27 to approve the mid-term performance.
Gelonghui on November 12 reported that clarity medical (01406.HK) announced it will hold a board of directors meeting on November 27, 2024 (Wednesday) to approve the interim results for the six-month period ending September 30, 2024, and to consider the proposal for the payment of an interim dividend (if any).